Search Results - "Deininger, Michael W.N."

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias by Cortes, Jorge E, Kantarjian, Hagop, Shah, Neil P, Bixby, Dale, Mauro, Michael J, Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I, Rivera, Victor M, Clackson, Tim, Turner, Christopher D, Haluska, Frank G, Druker, Brian J, Deininger, Michael W.N, Talpaz, Moshe

“…Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In…”
Get full text

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia by Druker, Brian J, Guilhot, François, O'Brien, Stephen G, Gathmann, Insa, Kantarjian, Hagop, Gattermann, Norbert, Deininger, Michael W.N, Silver, Richard T, Goldman, John M, Stone, Richard M, Cervantes, Francisco, Hochhaus, Andreas, Powell, Bayard L, Gabrilove, Janice L, Rousselot, Philippe, Reiffers, Josy, Cornelissen, Jan J, Hughes, Timothy, Agis, Hermine, Fischer, Thomas, Verhoef, Gregor, Shepherd, John, Saglio, Giuseppe, Gratwohl, Alois, Nielsen, Johan L, Radich, Jerald P, Simonsson, Bengt, Taylor, Kerry, Baccarani, Michele, So, Charlene, Letvak, Laurie, Larson, Richard A

“…The constitutively active BCR-ABL tyrosine kinase is the cause of chronic myeloid leukemia. Imatinib is the first small synthetic molecular inhibitor of the…”
Get full text

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia by Soverini, Simona, Branford, Susan, Nicolini, Franck E, Talpaz, Moshe, Deininger, Michael W.N, Martinelli, Giovanni, Müller, Martin C, Radich, Jerald P, Shah, Neil P

“…Abstract Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result…”
Get full text

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants by O'HARE, Thomas, WALTERS, Denise K, DRUKER, Brian J, STOFFREGEN, Eric P, TAIPING JIA, MANLEY, Paul W, MESTAN, Jürgen, COWAN-JACOB, Sandra W, LEE, Francis Y, HEINRICH, Michael C, DEININGER, Michael W. N

“…Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in…”
Get full text

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure by Hughes, Timothy P, Mauro, Michael J, Cortes, Jorge E, Minami, Hironobu, Rea, Delphine, DeAngelo, Daniel J, Breccia, Massimo, Goh, Yeow-Tee, Talpaz, Moshe, Hochhaus, Andreas, le Coutre, Philipp, Ottmann, Oliver, Heinrich, Michael C, Steegmann, Juan L, Deininger, Michael W.N, Janssen, Jeroen J.W.M, Mahon, Francois-Xavier, Minami, Yosuke, Yeung, David, Ross, David M, Tallman, Martin S, Park, Jae H, Druker, Brian J, Hynds, David, Duan, Yuyan, Meille, Christophe, Hourcade-Potelleret, Florence, Vanasse, K. Gary, Lang, Fabian, Kim, Dong-Wook

“…Asciminib, a novel ABL tyrosine kinase inhibitor that targets the myristoyl site of the molecule rather than the ATP-binding domain, showed mainly low-grade…”
Get full text

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy by Laudadio, Jennifer, Deininger, Michael W.N, Mauro, Michael J, Druker, Brian J, Press, Richard D

“…Although targeted inhibition of BCR-ABL with imatinib is an effective therapy for patients with chronic myeloid leukemia (CML), a minority of patients acquire…”
Get full text

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis by Gupta, Vikas, Mesa, Ruben A, Deininger, Michael W N, Rivera, Candido E, Sirhan, Shireen, Brachmann, Carrie Baker, Collins, Helen, Kawashima, Jun, Xin, Yan, Verstovsek, Srdan

“…Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily…”
Get full text

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I by Verstovsek, Srdan, Mesa, Ruben A, Gotlib, Jason, Levy, Richard S, Gupta, Vikas, DiPersio, John F, Catalano, John V, Deininger, Michael W N, Miller, Carole B, Silver, Richard T, Talpaz, Moshe, Winton, Elliott F, Harvey, Jr, Jimmie H, Arcasoy, Murat O, Hexner, Elizabeth O, Lyons, Roger M, Raza, Azra, Vaddi, Kris, Sun, William, Peng, Wei, Sandor, Victor, Kantarjian, Hagop

“…In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and…”
Get full text

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia by O'HARE, Thomas, DEININGER, Michael W. N, EIDE, Christopher A, CLACKSON, Tim, DRUKER, Brian J

“…Beginning with imatinib a decade ago, therapy based on targeted inhibition of the BCR-ABL kinase has greatly improved the prognosis for chronic myeloid…”
Get full text

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies by SCHITTENHELM, Marcus M, SHIRAGA, Sharon, SCHROEDER, Arin, CORBIN, Amie S, GRIFFITH, Diana, LEE, Francis Y, BOKEMEYER, Carsten, DEININGER, Michael W. N, DRUKER, Brian J, HEINRICH, Michael C

“…Activating mutations of the activation loop of KIT are associated with certain human neoplasms, including the majority of patients with systemic mast cell…”
Get full text

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I by Verstovsek, Srdan, Mesa, Ruben A, Gotlib, Jason, Levy, Richard S, Gupta, Vikas, DiPersio, John F, Catalano, John V, Deininger, Michael W N, Miller, Carole B, Silver, Richard T, Talpaz, Moshe, Winton, Elliott F, Harvey, Jr, Jimmie H, Arcasoy, Murat O, Hexner, Elizabeth O, Lyons, Roger M, Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Sun, William, Sandor, Victor, Kantarjian, Hagop M

“…COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with…”
Get full text

Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses by Cortes, Jorge E., Lomaia, Elza, Turkina, Anna, Moiraghi, Beatriz, Undurraga Sutton, Maria, Pavlovsky, Carolina, Rojas, Christine, Chuah, Charles, Arthur, Christopher Kevin, Apperley, Jane, Kim, Dong-Wook, Hochhaus, Andreas, Rousselot, Philippe H., Rosti, Gianantonio, Mauro, Michael J., Lipton, Jeffrey Howard, Naranjo, Daniel, Liu, Guohui, Srivastava, Shouryadeep, Deininger, Michael W.N.

“…Abstract only 7502 Background: In PACE (NCT01207440) heavily pretreated patients (pts) with chronic-phase CML (CP-CML) had deep, lasting responses to PON;…”
Get full text

A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response by Press, Richard D, Galderisi, Chad, Yang, Rui, Rempfer, Carole, Willis, Stephanie G, Mauro, Michael J, Druker, Brian J, Deininger, Michael W N

“…Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid leukemia patients in chronic phase. Although CCR is usually durable, a…”
Get full text

Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib by DEININGER, Michael W. N, O'BRIEN, Stephen G, FORD, John M, DRUKER, Brian J

“…The introduction of imatinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has dramatically changed the management of chronic myeloid leukemia (CML)…”
Get full text

Characterization of murine JAK2V617F-positive myeloproliferative disease by BUMM, Thomas G. P, ELSEA, Collin, CORBIN, Amie S, LORIAUX, Marc, SHERBENOU, Daniel, WOOD, Lisa, DEININGER, Jutta, SILVER, Richard T, DRUKER, Brian J, DEININGER, Michael W. N

“…The JAK2(V617F) mutation is present in almost all patients with polycythemia vera (PV), large proportions of patients with essential thrombocythemia and…”
Get full text

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia by Kovacsovics, Tibor J., Mims, Alice, Salama, Mohamed E., Pantin, Jeremy, Rao, Narayanam, Kosak, Ken M., Ahorukomeye, Peter, Glenn, Martha J., Deininger, Michael W.N., Boucher, Kenneth M., Bavisotto, Linda M., Gutierrez-Sanchez, Gerardo, Kennedy, Thomas P., Marcus, Stephen G., Shami, Paul J.

“…Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy…”
Get full text

Optimizing therapy of chronic myeloid leukemia by Deininger, Michael W.N

“…Chronic myeloid leukemia (CML) is caused by Bcr-Abl, a constitutively active tyrosine kinase that is the result of a reciprocal translocation between…”
Get full text

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation by Melo, Junia V, Deininger, Michael W N

“…Chronic myeloid leukemia (CML) is caused by the Bcr-Abl oncoprotein,the product of the t(9;22) chromosomal translocation that generates the Philadelphia…”
Get more information

The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells by Deininger, Michael W.N., Goldman, John M., Lydon, Nicholas, Melo, Junia V.

“…The Philadelphia chromosome found in virtually all cases of chronic myeloid leukemia (CML) and in about one third of the cases of adult acute lymphoblastic…”
Get full text

Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib by O'HARE, Thomas, WALTERS, Denise K, STOFFREGEN, Eric P, SHERBENOU, Daniel W, HEINRICH, Michael C, DEININGER, Michael W. N, DRUKER, Brian J

“…Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib. However, reactivation of Bcr-Abl via kinase domain mutations that reduce…”
Get full text